secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001628280-22-002707
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M
-----------------------------------------------------------------------

- Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).
- Q4 GAAP net income $32.1M (vs $26M); FY GAAP net income $112.5M (vs $106M). Non-GAAP Q4 $42.6M.
- 2022 revenue guidance $400-430M, implying 9-17% growth.
- Repurchased 10M shares for $207.5M in Q4; cash+investments $335.8M.
- Clinical: ovarian cancer Phase 3 start Q2 2022; AIWG Phase 2 data Q4 2022; NDA for Cushing's Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/0001628280-22-002707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/cort-20220215.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-002707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer